ADME and DMPK Services

At Concept Life Sciences, we deliver high-quality ADME, DMPK, pharmacokinetic (PK) and bioanalytical data that helps you identify liabilities sooner, optimize compounds more effectively, and confidently progress the best candidates.

With integrated drug discovery- chemistry, biology and ADME available under one roof, we are more than an ADME testing provider, we're a trusted scientific partner, with drug discovery expertise, responsive project management and flexible study design to help you accelerate better decisions throughout your program.

Not worked with us before?

Experience the quality of our ADME data and scientific support with our ADME Assay trial service.

‍

‍

Make better decisions earlier to maximize your drug discovery investment.

The value of ADME and DMPK isn't in generating more data, it's in generating the right data at the right time to guide your next decision.

Whether you're progressing compounds through hit-to-lead, lead optimization, or candidate selection, early, actionable insights help you understand compound behavior, reduce uncertainty, and keep your DMTA cycle moving. Our integrated ADME, DMPK, pharmacokinetic (PK) and bioanalysis services provide the data you need to confidently prioritize compounds, optimize medicinal chemistry, and reduce development risk before costly downstream studies.

The result - Better data, better decisions, better return on investment.

Built around your discovery program

Different organizations have different challenges, our ADME and DMPK services are designed to support both high-volume pharmaceutical portfolios and fast-moving biotech programs.

Why discovery teams choose Concept Life Sciences

Scientific partnership, not just data generation

Our scientists work as an extension of your discovery team. From study design through data interpretation, we help you understand what the results mean and how they should influence your next decision. You'll have direct access to experienced ADME and DMPK scientists throughout your project.

Responsive project management

Drug discovery priorities change rapidly. Our flexible approach allows studies to start quickly, adapt to changing priorities and deliver data in the formats that work best for your team. We offer:

• Simple compound submission.
• Call-off study models.
• Flexible reporting formats.
• Secure data delivery.
• Responsive communication throughout your project.

Less administration. More science.

High-quality, reproducible data

Confidence in your decisions starts with confidence in your data. Our validated ADME and DMPK workflows generate robust, reproducible datasets that support confident progression decisions across individual projects and large discovery portfolios.

Whether you're screening hundreds of compounds or investigating a single lead series, you can trust the quality of the data informing your program.

Integrated drug discovery expertise

Unlike standalone ADME providers, we combine chemistry, biology, ADME/DMPK and bioanalysis under one roof. This integrated approach enables:

• Better collaboration between scientific disciplines.
• Faster DMTA cycles.
• Fewer project handovers.
• More efficient decision-making.
• A single partner from discovery through candidate selection.

Watch the on-demand webinar that delves into the challenges and innovative solutions for predicting human pharmacokinetics and exposure, essential for clinical success. Learn how early identification of liabilities and a focus on exposure can significantly improve compound selection and reduce attrition rates, with the ADMET toolkit.

Supporting every stage of drug discovery

Our ADME and DMPK capabilities

Our integrated services include:

In vitro ADME - Generate predictive data to understand compound behavior early.

In vivo pharmacokinetics - PK studies in multiple species (IV/PO, single or cassette dosing), tailored to each program's stage, to characterize exposure, clearance and bioavailability, guiding compound selection through lead optimization to candidate selection..

Bioanalysis - Sensitive LC-MS/MS bioanalysis supporting pharmacokinetic studies, DMPK investigations and regulatory programs.

Why partner with Concept Life Sciences?

See the quality of our ADME data for yourself

Choosing a new CRO is an important decision. That's why we offer eligible organizations the opportunity to evaluate our scientific expertise, data quality and customer experience before committing to a larger program.

With our ADME assay testing services trial, you can:

• Experience our responsive scientific support and rapid decision-making before committing to a wider program.
• Benchmark the quality and reproducibility of our data against your existing workflows before expanding to larger screening campaigns.
• Evaluate our reporting and communication.
• See how easily we integrate into your DMTA workflow.

What our clients say

Concept Life Sciences ADME and DMPK services supported our hit-to-lead and lead optimization programs. Their team showed great expertise and professionalism, providing us with invaluable insights into our compounds. The data delivered was clear and actionable, enabling us to quickly make informed decisions. Their customer service and collaboration were outstanding, with tailored approaches and prompt communication. Concept Life Sciences' ADME and DMPK services have been instrumental in our research, making them a trusted partner in drug discovery.

SVP, UK Biotech

Ready to accelerate your discovery program?

Whether you need a single ADME study, support for lead optimization or a long-term scientific partner, we're here to help by offering you the chance to evaluate our service at no cost.

New to Concept Life Sciences? Evaluate before committing to a larger study with our Free ADME Assay Trial Find out if your project qualifies!

Already planning your next study? Discuss your project with one of our ADME and DMPK scientists: Request a Quote

ADMET and DMPK FAQs

Q: When should I start ADME and DMPK testing?

A: The earlier you generate ADME data, the earlier you can identify liabilities, establish structure ADME relationships and focus medicinal chemistry on compounds with the greatest chance of success.

Q: Can you support both high-volume screening and individual programs?

A: Yes. We support everything from large pharmaceutical discovery portfolios requiring scalable ADME profiling to fast-moving biotech programs that need rapid, decision-ready data.

Q: Can you integrate with our existing discovery workflow?

A: Absolutely. We offer flexible reporting formats, simple submission processes and direct scientific collaboration, making it easy to integrate our services into your existing workflows.

Q: How do your services help reduce project risk?

A: By providing high-quality ADME and DMPK data early in the discovery process, we help identify liabilities, guide optimization and improve confidence in progression decisions, reducing the risk of costly late-stage failures.

‍